<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000426.v1.p1" parentStudy="phs000426.v1.p1" createDate="2011-10-26" modDate="2011-12-09">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Mary V. Relling, PharmD</td><td>St. Jude Children&#39;s Research Hospital, Memphis, TN USA</td></tr>
		<tr><td>Funding Source</td><td>CA 21765</td><td>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U01 GM92666</td><td>National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>U01 HL65899</td><td>National Heart, Lung, Blood, Institute, National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>SLCO1B1 Variants and Methotrexate Clearance</StudyNameEntrez>
	<StudyNameReportPage>SLCO1B1 Variants and Methotrexate Clearance</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Cohort</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Methotrexate plasma concentration is related to its clinical effects. To identify the genetic basis of interindividual variability     in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL), we performed a genome-wide     analysis (GWAS) of 500,568 germline single-nucleotide polymorphisms (SNPs) in 434 children with ALL who received 3,014 courses of     methotrexate at 2 to 5 g/m2. SNPs were validated in an independent cohort of 206 patients. Adjusting for age, race, sex, and     methotrexate regimen, the most significant associations were with SNPs in the organic anion transporter polypeptide, <i>SLCO1B1</i>     (rs11045879 (P = 1.7 x 10<sup>-10</sup>) and rs4149081 (P = 1.7 x 10<sup>-9</sup>) (Trevino et al, PMID:     <a href="http://www.ncbi.nlm.nih.gov/pubmed/19901119" target="_blank">19901119</a>). To test whether rare variants in <i>SLCO1B1</i>     could alter its function, we genotyped <i>SLCO1B1</i> exons in a slightly larger group of 699 children with ALL who received     methotrexate and identified 93 single nucleotide polymorphisms (SNPs).  We found several common and rare non-synonymous (NS) SNPs     associated with methotrexate clearance.</p>     <p>NS SNPs predicted to be functionally damaging (common or rare) were more likely to be found among patients with the lowest     adjusted methotrexate clearance (lowest 10%) than patients with high clearance (highest 10%).  Four <i>SLCO1B1</i> haplotypes were     associated with reduced methotrexate clearance and we verified that these haplotypes have lower function with in vitro transport assays.     We were able to quantitatively account for a third of the population variability in clearance of methotrexate with clinical and     genetic covariates.  This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from     arrays, sequencing, and genotyping.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>       <ul>         <li>Participant has a confirmed diagnosis of non-B-cell acute lymphoblastic leukemia (ALL)</li>         <li>Participant is less than or equal to 18 years of age</li>         <li>Written, informed consent following NCI, IRB, FDA, and OPRR Guidelines</li>         <li>Patient received high-dose methotrexate as part of protocol-directed therapy for ALL</li>       </ul>     </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="19901119"/>
		</Publication>
		<Publication>
			<Pubmed pmid="21387541"/>
		</Publication>
		<Publication>
			<Pubmed pmid="19022939"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22147369"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Acute Lymphoblastic Leukemia"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Mary V. Relling, PharmD</AttName>
			<Institution>St. Jude Children&#39;s Research Hospital, Memphis, TN USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>CA 21765</AttName>
			<Institution>National Cancer Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 GM92666</AttName>
			<Institution>National Institute of General Medical Sciences, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>U01 HL65899</AttName>
			<Institution>National Heart, Lung, Blood, Institute, National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>Patients treated on two clinical trials are included here.  Total XIIIB included consolidation therapy of two weekly doses of     methotrexate (2 g/m2 over 2 hours, followed by leucovorin) and 6-mercaptopurine (75 mg/m2 per night for 2 weeks)(Pui et al. 2004     Blood 104(9): 2690-2696. PMID: <a href="http://www.ncbi.nlm.nih.gov/pubmed/15251979" target="_blank">15251979</a>;     Kishi et al. 2007 Blood 109(10): 4151-4157. PMID: <a href="http://www.ncbi.nlm.nih.gov/pubmed/17264302" target="_blank">17264302</a>).     Subsequent therapy included identical methotrexate and 6-mercaptopurine doses administered every 8 weeks up to 1 year. Total XV     included four doses of methotrexate during consolidation, each given over 24 hours with dosage adjusted to achieve a steady-state     plasma concentration of 33 &#181;M (low-risk arm) or 65 &#181;M (standard/high-risk arm) (Pui et al. 2009     N Engl J Med 360(26): 2730-2741. PMID: <a href="http://www.ncbi.nlm.nih.gov/pubmed/19553647" target="_blank">19553647</a>).     </p>     <p>Total XIIIB first patient enrolled: August 1994<br/>     Total XIIIB last patient enrolled: July 1998<br/>     Total XV first patient enrolled: July 2000<br/>     Total XV last patient enrolled: October 2007     </p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="BRU" longName="Biomedical Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIGMS</DacName>
      <DacFullName>National Institute of General Medical Sciences DAC</DacFullName>
      <DacEmail>NIGMSDBGAPDataAccessCommitee@mail.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000426.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
               http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000426.v1.p1
            </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000426.v1.p1" FileName="Data_Use_Certification_Agreement_mtx.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Biomedical Research Use</ConsentName>
        <ConsentAbbrev>BRU</ConsentAbbrev>
        <UseLimitation>Use of dataset is limited to biomedical research use only.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
